A series of 16 new ethyl β-amino benzimidazole acrylate derivatives 12(a-p) with a (2E)-s-cis/trans conformation and bearing two points of diversity was designed and synthesized by using a multi-step strategy (reductive amination, deprotection in acidic media and transamination) in moderate to good yields from ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate (5) and monosubstituted N -Boc diamines (7a,7b) as starting building blocks. Products 12 were evaluated for their in vitro cytotoxic potential against six selected human cell lines (Huh7-D12, Caco2, MDA-MB231, HCT116, PC3 and NCI-H727). Compounds 12a, 12e and 12l exhibited selective and micromolar antitumor activities against Huh7-D12 and Caco2 cell lines.
Introduction
Benzimidazole is a heterocyclic scaffold consisting of a benzene and an imidazole ring. During the last decades, benzimidazole has gained considerable attention by the pharmaceutical community, and this is confirmed by recent reports in the literature that describe the "therapeutic evolution of their derivatives in pre-clinical and clinical trials during the last quinquennial period" [1, 2] . Medicinal aspects B Jean-Pierre Bazureau jean-pierre.bazureau@univ-rennes1.fr 1 and structure activity relationship (SAR) of benzimidazole have been reviewed by Yadav and Ganguly [3] . Owing to that cancer is the second major cause of death worldwide [4] , chemical and pharmaceutical researchers investigated the synthesis of bioactive benzimidazole derivatives with significant cytotoxic effects. As an example in Fig. 1 , bendamustine (I) is abenzimidazole-based drug approved for chronic lymphoid leukemia treatment [5] . Compound II developed by Sharma et al. [6] was identified as benzimidazole derivative that exhibited in vitro cytotoxic activity against MDA-MB231 cell line with a half inhibitory concentration (IC 50 ) value of 3.3 μM. The new 5-fluorine benzimidazole-4-carboxamide derivative III was reported as a promising anticancer agent and showed promising cell inhibitory activity against HCT116 cell with an IC 50 of 7.4 μM [7] . Introduction of a purine moiety in benzimidazole derivative IV was found to exhibit growth inhibitory activity toward Aurora-A kinase with an IC 50 value of 10 nM [8] . Varshney et al. investigated the multi-step synthesis of 1-[(5-alkenyl/hydroxyalkenyl substituted-1,3,4-oxadiazol-2-yl) -methyl]-2-methyl-1H -benzimidazoles and found that compound V was the most bioactive benzimidazole derivative [9] against human breast adenocarcinoma (MCF-7 cell, IC 50 = 40 μM) and human cervical carcinoma (HeLa) cell lines (IC 50 = 5.3 μM). Introduction of a 4-amino-quinolyl fragment to benzimidazole at the C-4 position in compound VI exhibited inhibitory activity against VEGFR-2 (IC 50 = 30 nM) associated to anticancer activity against MCF-7 cancer cells (IC 50 = 1.3 μM) [10] . Stimulated by these pharmaceutical applications for benzimidazole scaffold bearing specific groups as bioactive compounds against a variety of cancer cell lines, our goal was to explore the construction of stereocontrolled β-amino benzimidazole acrylates [11] (Fig. 2) bearing, a flexible diamino linker and a variable N -arylmethyl moiety.
Our retrosynthetic strategy toward new N -functionalized β-amino benzimidazole acrylate derivatives shows two possible routes. Route A is based on a transamination reaction between β-dimethylamino benzimidazole acrylates (building block A) and a mono N -substituted diamine. Route B involves the reductive amination of amino-linked benzimidazole acrylate with aromatic aldehydes. Considering these two routes to build N -functionalized β-amino benzimidazole acrylates for this project, it can be observed that the β-dimethylamino benzimidazole acrylate will be used as building block for the two routes A and B. Herein, we present the synthetic results for the preparation of these new benzimidazole derivatives, their intermediates and their biological activities as potential cytotoxic agents. 
Results and discussion

Chemistry
Synthesis of building blocks A and B:
The strategy for the synthesis of ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate 5 as building block A and N -Boc diamines 7(a, b) as building block B is outlined in Scheme 1. Access to 5 was achieved in three steps. The first step is based on a modified protocol for the classic Pinner reaction. Ethyl cyanoacetate 1 is converted into ethyl 2-ethoxycarbonylacetimidate hydrochloride 2 in acidic conditions by addition of acetyl chloride (compound 1 in dry absolute EtOH) to generate in situ hydrochloric acid at 0 • C. After 2 h, the reaction mixture was concentrated in vacuum and a product crystallized rapidly in multigrams quantities of desired imidate hydrochloride 2 (58% yield). This salt underwent facile heterocyclocondensation with commercially available ortho-phenylenediamine 3 in refluxed methylene chloride during 48 h to give ethyl 2-(1H -benzimidazol-2-yl)acetate 4 (27% yield) [12] . Finally, the desired building block 5 was easily prepared according to a previous method developed in our laboratory [13] . This solvent-free protocol consisted in reacting compound 4 with N , N -dimethylformamide diethyl acetal (DMF-DEA) at 90 • C for 30 min under microwave irradiation conditions [14] . After purification by recrystallization from AcOEt (82% yield), the structure of ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate 5 was ascertained by HRMS, 1 H and 13 C NMR. Building block 5 was prepared with an overall yield of 13% in multi-gram quantities.
Next, the preparation of 7(a,b) was pursued using commercially available diamines 6a and 6b. Routes A and B involve the use of monoprotected diamines 7(a,b); we chose the N -Boc protecting group because it is effectively removed in acid conditions. Tert-butyl {2- [4-(3-aminopropyl) pyperazin-1-yl]propyl}carbamate 7a and tertbutyl (3-aminopropyl)carbamate 7b were synthesized according to the literature [15, 16] . Treatment of diamines 6a and 6b with di-tert-butyldicarbonate (Boc) 2 O in 1,4-dioxane at room temperature for 24 h produced mainly mono-N -Boc protected diamines 7a (56% yield) and 7b (80% yield).
Synthesis of ethyl N-functionalized β-amino benzimidazole acrylate derivatives 12 using Route A: In Scheme 2, our main task was to accomplish a reliable synthesis of mono Nsubstituted diamines 11 possessing two points of diversity. To obtain a sufficient number of compounds suitable for a preliminary biological screening, we selected a series of aromatic aldehydes 8 containing a variety of electron-donating substituents for 8(a-f), electron-withdrawing substituents for 8(g-i), without substituents (8l), and heteroaromatic aldehydes 8(j,k) to introduce molecular diversity on the phenylmethyl moiety of the desired products 11(a-p). The preparation of 9 was easily conducted by reaction of mono-N -Boc protected diamine 7a or 7b with an appropriate number of equivalents of aldehyde 8 in MeOH under microwave irradiation conditions. After 45 min at 90 • C, we obtained desired arylaldimines 9(a-p) (68-98% yields, Table 1 ).
Next, transforming arylaldimines 9(a-p) into mono-Nprotected diamines 10(a-p) was accomplished with 5 equivalents of NaBH 4 in MeOH at 50 • C for 24 h [17] . Compounds 10(a-p) were obtained as crystallized or viscous products in yields ranging from 73 to 98%. For deprotection of the NBoc group in compounds 10(a-p), we employed a solution of 6M HCl in 1,4-dioxane at room temperature for 4 h. This straight forward protocol afforded expected hydrochloride salts 11(a-p) in good yields (63-98%) without impurities or by-products especially for compounds 11(a-d).
With the hydrochloride salts of mono N -substituted diamines 11(a-p) in hand, our focus was the transformation of ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate 5 into desired compounds 12 by transamination. Typically, the mechanism of this reaction is an additionelimination [18] after the loss of dimethylamine via an aminal intermediate, which could not be isolated [13] . In previous work, we used 5 as an ambident synthon in a regioselective aza-annulation with isocyanate for the preparation of 1-oxo-1,2-dihydropyrimido[1,6−a]benzimidazole-4-carboxylates using solvent-free conditions under microwave irradiation [19] . This solvent-free aza-annulation was also extended to mono N -substituted hydrazines in the synthesis of new 4-(1H -benzimidazol-2-yl)-1,2-dihydro-(3H )-pyrazol-3-ones [20] . Based on these results, we decided to examine the reactivity of 5 with mono N -substituted diamines 11 in solution phase under microwave because microwave-assisted organic synthesis (MAOS) [21] has shown to dramatically reduce reaction times and improve product yields and ratios. Unfortunately, all microwave reaction attempts in a closed vessel using a polar or a nonpolar solvent (EtOH, MeCN, CH 2 Cl 2 ), different temperatures (40-80 • C) and reaction times (40-80 min), only afforded 12 in poor conversion (∼5-10%).
We then decided to use classic heating by using an oil bath and magnetic stirring. For salts 11(a-d), two equivalents of di-iso-propyl ethylamine (DIPEA) and a reaction time of 24 h were required and, for the remaining salts 11(e-p), 1.1 equivalent of DIPEA and a reaction time ranging from 4 to 6 h gave good results for the furnishing of compounds 12(e-p) (see experimental section for details).
As seen from the results in Table 2 , we obtained a library of 16 new β-amino benzimidazole acrylate derivatives 12 in low yields (10-38%) for 12(b,c),12(f-i),12k and 12(m, n); in moderate yields (42-63%) for 12e,12j and 12l, and in good yields (61-93%) for 12a,12d and 12(o,p). of the identities of these compounds 12(a-p) were confirmed by 1 H, 13 C NMR and HRMS analyses. All the N -functionalized β-amino benzimidazole acrylates derivatives 12(a-p) adopted a characteristic (2E) − s-cis/trans conformation (Scheme 1), which is stabilized by an intramolecular hydrogen bond, as indicated by the strong downfield shifted resonance of the NH group on C-3 (12a, δNH = 11.78 ppm in 1 H NMR spectrum using DMSO-d 6 ). It is noteworthy that a coupling constant 3 J HH = 13.5 Hz in 12a between the amino group on C-3 and H-3 (δ H −3 = 8.10 ppm) indicate a trans-relationship [22] . The shift of NH in benzimidazol-2-yl moiety (12a, δNH = 10.8 ppm) accounted also for an intramolecular hydrogen bound with the C=O of the acrylate ester function and enhanced the stability of the (2E) − s-cis/trans conformation. The planar character of this (2E) − s-cis/trans conformation is associated to a strong polarization of the C-2/C-3 bond (12a, δC−2 = 85.4 ppm and δC−3 = 154.2 ppm) and confirmed a "pushpull" effect [23] . Route B as possible alternative process for the synthesis of ethyl N-functionalized β-amino benzimidazole acrylate derivatives 12: In route A, the construction of compounds 12 is based on reductive amination, deprotection transamination reactions and we think that it will be interesting to explore an alternative route according to Scheme 3. Starting ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate 5 reacted smoothly with tert-butyl (3-aminopropyl)carbamate 7b in refluxing dry methylene chloride for 48 h. After concentrating the reaction mixture in vacuum, the crude product 13 Table 1 Results for the preparation of intermediates 9(a-p), 10(a-p), hydrochloride salts 11(a-p) and products 12(a-p) in Route A Table 2 ).
In the second step, carbamate 13 was deprotected in acidic conditions as used in route A (6M HCl in 1,4-dioxane at 25 • C for 4 h) affording hydrochloride salt 14 in 72% yield.
Next, the condensation of amino hydrochloride salt 14 with 3,4-(methylenedioxy)benzaldehyde 8a was conducted under microwave irradiation at 90 • C in the presence of 1.1 equivalent of DIPEA. After 45 min, this microwave process afforded 15 in 84% yield without modification of the (2E)-s-cis/trans conformation. Finally, applying the reduction reaction conditions used in route A (MeOH, 5 equivalents of NaBH 4 , 50 • C, 24 h) to convert 15 into secondary 12e, analysis of the crude reaction mixture by 1 H NMR in DMSO-d 6 solution showed a conversion of 51% for 12e together with by-products. After purification of 12e (∼ 25-30% yield), we continued to explore another parameters of reaction conditions for reduction (ratio NaBH 4 /product 15, temperature and reaction time), and we were not able to increase the performance and the quality for this aldimine reduction. In fact, it is possible that benzimidazole and β-amino acrylate moieties of 15 do not tolerate the reduction conditions. On the basis of these results, route A is more practicable for purification of intermediates in each step.
Cytotoxic assays
All the new N -functionalized β-amino benzimidazole acrylates derivatives 12(a-p) were evaluated for their in vitro cytotoxic potential against six selected human cancer cell lines, namely hepatocellular carcinoma (Huh7 D12), colorectal adenocarcinoma (Caco 2), colorectal carcinoma (HCT 116), breast (MDA MB231), prostate (PC3) and lung (NCI-H727). The percentage of cell survival was measured at single dose of 25 μM, and IC 50 values were determined for those compounds exhibiting a survival percentage below 50% in 3 assays, using roscovitine as reference (Table 3) .
It is observed from the primary screening results in Table 3 that compounds 12 exhibited antitumor activities in several tumor cell lines with IC 50 lower than 10 μM. A brief survey of these results can be divided in two categories: compounds 12(a-d) bearing a N , N -bis-propyl(piperazin-1-yl) linker and products 12(e-p) with the shorter N -propyl linker.
For the first group (Fig. 3) , only 12a presented a selective activity against Huh7-D12 cell lines (IC 50 = 4 μM). Compound 12c showed also an impact on Huh7-D12 with a similar IC 50 of 4 μM and exhibited cytotoxicity on NCI-H727 cell line (IC 50 = 5 μM). On the other hand, 12b and 12d were unselective because both were found to be active on Huh7-D12, MBA-MB231, HCT116 and NCI-H727 cell lines (Table 3 , Fig. 3 ). For the second group in Table 2 , it could be observed that four compounds among the series 12(e-p) with N -propyl linker exhibited selective cytotoxicities. The presence of a 2-chlorophenyl moiety in compound 12l displayed potential cytotoxicity on colorectal adenocarcinoma (Caco2) with IC 50 3 μM. The second selective derivative is 12e. This one is active on Huh7-D12 cell lines with IC 50 = 5 μM. For compounds 12g and 12j, the selectivity is moderate but both showed cyctotoxicity against Huh7-D12 and Caco2 cell lines (12g: Huh7-D12, IC 50 = 3 μM and Caco2 IC 50 = 4 μM; 12j: Huh7-D12, IC 50 = 4 μM and Caco2 IC 50 = 2 μM). It could be noticed that derivatives 12a and 12e bearing a benzo [1, 3] dioxo-5-yl moiety showed selective cytotoxicity against Huh7-D12 in a similar manner, which means the length and the nature of the linker had a minor role in the cytotoxic activity.
Lastly, comparison of compounds 12d and 12l showed that the position of Cl on the phenylmethylamino group associated to the length and the nature of linker has an important effect on cytotoxicity. (9) 11 (8) 13 (7) 34 (10) 27 (9) 
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Conclusion
In summary, we have developed a series of new Nfunctionalized β-amino benzimidazole acrylate derivatives from ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl) acrylate and two monosubstituted N -Boc diamines as building blocks. Two convergent routes were investigated with these building blocks. Route "A" was more efficient for this multi-step synthesis of these benzimidazole derivatives based on successive reductive amination, acidic N -Boc deprotection and transamination. This process offered the possibility of preparing a library of sixteen N -functionalized β-amino benzimidazole acrylate derivatives bearing two points of diversity (the first is the linker issued from the diamine and the second is an arylmethylamino moiety). All the new benzimidazole derivatives were analyzed by 1 H and 13 C NMR and presented a (2E)-s-cis/trans conformation associated to a strong polarization of the C-2/C-3 double bond by a pushpull effect. The 16 new synthesized compounds were evaluated for their in vitro cytotoxic potential against six representative human tumoral cell lines, and 8 of them were found to be active against Huh7-D12, MDA-MB231, NCI-H727, HCT116 and Caco2 with IC 50 below 5 μM. Among the bioactive compounds, 12a, 12e and 12l turned out to be interesting because they presented selective micromolar inhibition activity on Huh7-D12 (12a: IC 50 = 4 μM and 12e: IC 50 = 5 μM) and Caco2 (12l: IC 50 = 3 μM). The current results for these 3 bioactive compounds have the potential to be developed as cytotoxic agents, and their structural modification could lead to the generation of promising anticancer agents.
Experimental
Chemistry section
General information Melting points were determined on a Kofler melting point apparatus and were uncorrected. Thinlayer chromatography (TLC) was accomplished on 0.2-mm precoated plates of silica gel 60 F-254 (Merck). Visualization was made with ultraviolet light (254 and 365 nm) or with a fluorescence indicator. 1 H NMR spectra were recorded on BRUKER AC 300 P (300 MHz) spectrometer, 13 C NMR spectra on BRUKER AC 300 P (75 MHz) spectrometer. Chemical shifts are expressed in parts per million downfield from tetramethylsilane as an internal standard. Data are given in the following order: δ value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), number of protons, coupling constants J is given in Hertz. High resolution mass spectra (HRMS) were recorded in positive mode using direct Electrospray infusion, on a Waters Q-Tof 2 or on a Thermo Fisher Scientific Q-Exactive spectrometers at the "Centre Régional de Mesures Physiques de l'Ouest" ScanMAT UMS 2001 (CRMPO ScanMAT UMS 2001, Rennes, France). Microwave reactions (S2 Wave platform SFS ScanMAT, Rennes) were carried out using an Anton Paar Monowave 300 microwave reactor (Anton Paar France) using 10-mL borosilicate glass vials equipped with snap caps. Preparative chromatography was carried out using a Combi Flash R f 200 psi (Serlabo Technologies France) using pre-packed column of silica gel 60 F 254 Merck equipped with a DAD UV/Vis 200-360 nm detector. Elemental analyses were performed on a Flash Microanalyzer EA1112 CHNS/O Thermo Electron in the "Centre Régional de Mesures Physiques de l'Ouest" (CRMPO, Rennes). Solvents were evaporated using a BUCHI rotary evaporator. All reagents and solvents were purchased from Acros, Aldrich Chimie, and Fluka France and were used without further purification.
Ethyl 2-ethoxycarbonylacetimidate hydrochloride (2)
The synthesis was carried out in a 250-mL two-necked roundbottomed flask, charged with magnetic stirrer and fitted with a condenser. To a stirred (400 rpm) solution of ethyl cyanoacetate 1 (17.3443 g, 16.3 mL, 153.34 mmol) 
Ethyl 2-(1H-benzimidazol-2-yl)acetate (4)
The synthesis was carried out in a 500-mL round-bottomed flask, charged with a magnetic stirrer and fitted with a condenser. A suspension of ethyl 2-ethoxycarbonyla cetimidate hydrochloride 2 (22 g, 112.4 mmol) and orthophen ylenediamine 3 (12.1603 g, 112.4 mmol) in 230 mL of dry methylene chloride was stirred vigorously (500 rpm) under reflux for 48 h. After removing all insolubles (ammonium chloride and unreacted products) by filtration, the volatiles were removed using a rotary evaporator under reduced pressure. To the resulting crude residue (which crystallized after standing), 20 mL of diethyl ether was added and the mixture was triturated for 15-20 min. 
Ethyl 3-dimethylamino-2-(1H-benzimidazol-2-yl)acrylate (5)
In a 10-mL glass tube were placed successively ethyl 2-(1H -benzimidazol-2-yl)acetate 4 (2 g, 9.8 mmol) and dimethylformamide diethylacetal DMF-DEA (1.7313 g, 2
Fig. 3
Compounds 12(a-e), 12g, 12j, 12l and their antitumor activities mL, 11.8 mmol, 1.2 equiv). The glass tube was sealed with a snap cap and placed in a Monowave 300 Anton Paar microwave reaction chamber. The reaction mixture was irradiated at 90 • C (P = 800 Watt) for 30 min under vigorous magnetic stirring. Then, the volatiles were removed using a rotary evaporator under reduced pressure. The crude residue, which crystallized after standing at room temperature, was rinsed with AcOEt (3 × 20 mL), the resulting material was collected by filtration in a Büchner funnel, and dried under high vacuum (10 −2 Torr) at 25 • C for 2 h. Recrystallization from AcOEt afforded ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate (5) 
Tert-butyl {2-[4-(3-aminopropyl)piperazin-1-yl]propyl} carbamate (7a)
Compound 7a was prepared in 56% yield as a colorless oil according to a previous procedure developed in our laboratory [15] . 
Tert-butyl (3-aminopropyl)carbamate (7b)
Compound 7b was prepared in 80% yield according to a previous procedure developed in our laboratory [16] as a colorless oil, and then it was stocked at 4 • C as a solution (2 g/mL) in dry ether. 
General procedure under microwave irradiation for the solution phase synthesis of aldimines 9(a-p)from tert-butyl (4-aminobutyl)carbamate 7(a, b)with a series of aromatic aldehyde 8(a-l).
In a 10-mL glass tube (for microwave synthesis) were placed successively tert-butyl {2- [4-(3-aminopropyl) Tert-butyl [3-(4-{3-[(benzo[1,3] 
Compound 9a was prepared in 90% yield as a viscous orange oil from tert-butyl {2- [4-(3-aminopropyl) Tert-butyl [3-(4-{3-[(4-methoxybenzylidene) 
amino]propyl} piperazin-1-yl)propyl]carbamate (9b)
Compound 9b was prepared in 68% yield as orange oil from tert-butyl {2- [4-(3-aminopropyl) 8.19 (s, 1H, N=CH, . 13 Tert-butyl [3-(4-{3-[(4-methylbenzylidene) 
Tert-butyl [3-(4-{3-[(4-chlorobenzylidene)amino]propyl}pi-perazin-1-yl)propyl]carbamate (9d)
Compound 9d was prepared in 87% yield pale brown oil from tert-butyl {2- [4-(3-aminopropyl) 8.24 (s, 1H, N=CH, . 13 [1, 3] 
Tert-butyl {3-[(Benzo
dioxol-5-ylmethylene)amino]propyl}carbamate (9e)
Compound 9e was prepared in 99% yield as yellowish oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 3,4-(methylenedioxy)benzaldehyde 8a (1 equiv.) 13 (s, 1H, N=CH, . 13 
Tert-butyl {3-[(3-methoxybenzylidene)amino]propyl} carbamate (9g)
Compound 9g was prepared in 96% yield as yellow oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 3-methoxybenzaldehyde 8c (0.95 equiv.) 1H, J = 1.2, 7.6 Hz, Ar); 2H, ; Ar); 8.26 (t, 1H, J = 1.3 Hz, N=CH, H-4). 13 -butyl {3-[(3,5-dimethoxybenzylidene) 
Tert
amino]propyl} carbamate (9h)
Compound 9h was prepared in 92% yield as amorphous yellowish oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 3,5-dimethoxybenzaldehyde 8d (0.98 equiv.) according to the standard procedure under microwave irradiation. 1 H NMR (CDCl 3 ) δ: 1.43 (s, 9H, (CH 3 ) 3 CO); 1.88 (quint, 2H, J = 6.6 Hz, 2H, 2H, J = 0.83, 6.5 Hz, -butyl {3-[(3,4,5-trimethoxybenzylidene) 
Tert
Tert-butyl {3-[(4-methylbenzylidene)amino]propyl} carbamate (9j)
Compound 9j was prepared in 98% yield as yellow-orange oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 4-methylbenzaldehyde 8f (0.95 equiv.) 2H, J = 7.8 Hz, Ar); 2H , J = 8.1 Hz, H-2 , H-6 , Ar); 8.23 (s, 1H, N=CH, H-4). 13 
Tert-butyl {3-[(4-chlorobenzylidene)amino]propyl} carbamate (9k)
Compound 9k was prepared in 96% yield as yellowish oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 4-chlorobenzaldehyde 8g (0.98 equiv.) 
Tert-butyl {3-[(4-cyanobenzylidene)amino]propyl} carbamate (9m)
Compound 9m was prepared in 91% yield as yellowish viscous oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and 4-cyanobenzaldehyde 8i (1 equiv.) according to the standard procedure under microwave irradiation. 1 H NMR (CDCl 3 ) δ: 1.42 (s, 9H, (CH 3 ) 3 CO); 1.88 (quint, 2H, J = 6.6 Hz, H-2); 3.22-3.27 (m, 2H, H-1); 3.68-3.73 (m, 2H, H-3); 4.95 (br s, 1H, NH); 7.67-7.7 (m, 2H, H-3 , H-5 , Ar); 7.80-7.83 (m, 2H, H-2 , H-6 , Ar); 8.30 (s, 1H, N=CH, H-4). 13 
Tert-butyl {3-[(pyridin-4-ylmethylene)amino]propyl} carbamate (9n)
Compound 9n was prepared in 88% yield as orange viscous oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and pyridine-4-carbaldehyde 8j (0.98 equiv.) 
Tert-butyl {3-[(quinolin-8-ylmethylene)-amino]-propyl} carbamate (9o)
Compound 9o was prepared in 96% yield as brownish deliquescent powder from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and quinoline-8-carbaldehyde 8k (0.95 equiv.) according to the standard procedure under microwave irradiation. 1 13 
Tert-butyl [3-(benzylidene-amino)propyl]carbamate (9p)
Compound 9p was prepared in 97% yield as dark orange viscous oil from tert-butyl (3-aminopropyl)carbamate 7b (1 equiv.) and benzaldehyde 8l (0.98 equiv.) 
Standard procedure for reduction of aldimines 9(a-p)into N-Boc monoprotected diamines 10(a-p)
All the reduction reactions were conducted in a 10-mL twonecked round-bottomed flask, charged with a magnetic stirrer and fitted with a condenser. Aldimine 9 (0.5 mmol, 1 equiv.) was solubilized in methanol (6-8 mL) under vigorous stirring (500 rpm) and cooled at 0 • C. To this solution were added small portions of NaBH 4 (0.094 g, 2.5 mmol, 5 equiv.) over a period of 10 minutes. The resulting suspension was stirred at 50 • C for 24 h (monitored by TLC on 0.2-mm precoated plates of silica gel 60 F-254, Merck). After cooling down to room temperature, volatiles were removed under reduced pressure using a rotary evaporator. Deionized water (8-12 mL) was added to the residue and the resulting mixture was transferred into a separating funnel. An extraction was conducted using dichloromethane (3× 6-8 mL), the combined organic phases were dried over magnesium sulfate MgSO 4 , filtered using a filter paper, and the solvent was removed in vacuo. The crude residue was dried under high vacuum (10 −2 Torr) at 25 • C for 2 h. The desired N -Boc monoprotected diamines 10 were obtained as viscous oils that crystallized on standing and was used further without purification. [3-(4-{3-[(benzo [1, 3] 
Tert-butyl
dioxol-5-ylmethyl)amino] propyl}piperazin-1-yl)propyl]carbamate (10a)
Compound 10a was prepared in 84% yield as orangeyellowish oil from 9a according to the standard procedure for reduction. 1 13 
Tert-butyl (3-{4-[3-(4-methoxybenzylamino)propyl] piperazin-1-yl}propyl)carbamate (10b)
Compound 10b was prepared in 79% yield as yellowish oil from 9b according to the standard procedure for reduction. 1 13 Tert-butyl (3-{4-[3-(4-methylbenzylamino) (C-2) ; 27.1 (C-7) ; 28.6 ((CH 3 ) 3 CO); 40.2 (C-1); 48.2 (C-8); 53.3-53.5 (C-4, C-5) ; 53.8 (C-9) ; 57.0-57.2 (C-3, C-6) Tert-butyl (3-{4-[3-(4-chlorobenzylamino) 
propyl] piperazin-1-yl}propyl)carbamate (10d)
Compound 10d was prepared in 90% yield as orange-yellow oil from 9d according to the standard procedure for reduction. [1, 3] 
dioxol-5-yl)methylamino] propyl}carbamate (10e)
Compound 10e was prepared in 80% yield as orange-yellow oil from 9e according to the standard procedure for reduction. 1 Tert-butyl [3-(4-methoxybenzylamino) Tert-butyl [3-(3-methoxybenzylamino) 13 Tert-butyl [3-(3,5-dimethoxybenzylamino) 
propyl]carba mate (10h)
Compound 10g was prepared in 80% yield as yellowish oil from 9h according to the standard procedure for reduction. 1 13 Tert-butyl [3-(3,4,5-trimethoxybenzylamino) 
Tert-butyl [3-(4-methylbenzylamino)propyl]carbamate (10j)
Compound 10j was prepared in 98% yield as pale yellow oil from 9j according to the standard procedure for reduction. 1 
Tert-butyl [3-(4-chlorobenzylamino)propyl]carbamate (10k)
Compound 10k was prepared in 87% yield as pale yellow oil from 9k according to the standard procedure for reduction. 1 
Tert-butyl [3-(2-chlorobenzylamino)propyl]carbamate (10l)
Compound 10l was prepared in 75% yield as pale yellow oil from 9l according to the standard procedure for reduction. 1 Tert-butyl [3-(4-cyanobenzylamino) 
propyl]carbamate (10m)
Compound 10m was prepared in 70% yield as yellowish oil from 9m according to the standard procedure for reduction. 1 H NMR (CDCl 3 ) δ: 1.43 (s, 9H, (CH 3 ) 3 CO); 1.58 (br s, 1H, NH); 1.65 (quint, 2H, J = 6.3 Hz, H-2); 2.67 (t, 2H, J = 6.5 Hz, H-3); 3.18-3.24 (m, 2H, H-1); 3.82 (s, 2H, H-4); 5.10 (br s, 1H, NH); 7.47-7.40 (m, H-2 , H-6 , Ar); 7.57-7.62 (m, H-3 , H-5 , Ar). 13 
Tert-butyl {3-[(pyridin-4-yl)methylamino]propyl}carba mate (10n)
Compound 10n was prepared in 80% yield as pale yellow oil from 9n according to the standard procedure for reduction. 1 
Tert-butyl {3-[(quinolin-8-ylmethyl)amino]propyl}carba mate (10o)
Compound 10o was prepared in 88% yield as brownish oil from 9o according to the standard procedure for reduction. 1 H NMR (CDCl 3 ) δ: 1.42 (s, 9H, (CH 3 ) 3 CO); 1.69 (quint, 2H, J = 6.6 Hz, H-2); 2.18 (br s, 1H, NH); 2.73 (t, 2H, J = 6.7 Hz, H-3) 3.18-3.24 (m, 2H, H-1); 4.34 (s, 2H, H-4); 5.31 (br s, 1H, NH); 1H, J = 4.2, 8.3 Hz, Ar); 1H, J = 7.1, 8.1 Hz, Ar); 1H, J = 7.0 Hz, Ar); 1H, J = 1.4, 8.2 Hz, Ar); 1H, J = 1.8, 8.3 Hz, Ar); (dd, 1H, J = 1.8, 4.2 Hz, H-2 , Ar). 13 
Tert-butyl (3-benzylaminopropyl)carbamate (10p)
Compound 10p was prepared in 73% yield as dark orange oil from 9p according to the standard procedure for reduction. 1 H NMR (CDCl 3 ) δ: 1.44 (s, 9H, (CH 3 ) 3 CO); 1.63-1.72 (m, 2H, H-2); 1.77 (br s, 1H, NH); 2.71 (t, 2H, J = 6.5 Hz, H-3); 3.21-3.23 (m, 2H, H-1); 3.77 (s, 2H, H-4); 5.34 (br s, 1H, NH); 7.22-7.33 (m, 5H, H-2 , H-3 , H-4 , H-5 , H-6 , Ar). 13 C NMR (CDCl 3 ) δ: 28.6 ((CH 3 ) 3 CO); 29.7 (C-2); 39.5 (C-1) ; 47.5 (C-3) ; 54.1 (C-4); 79.1 ((CH 3 ) 3 CO) ; 127.1 (C-4 , Ar); 128.3 (C-2 , C-6 , Ar); 128.5 (C-3 , C-5 10(a-p)into their hydrochloride salts 11(ap) Deprotection of N -Boc compounds 10(a-p) was realized according to a method of literature [15] , which involved the use of a solution of 6M HCl in 1,4-dioxane. After acidic treatment and work-up, the desired hydrochloride salt 11 was dried under high vacuum (10 −2 Torr) at 25 • C, then was stocked at 4 • C under nitrogen.
Standard procedure for deprotection of N-Boc monoprotected diamines
{3- piperazin-1-yl]-propyl}benzo [1, 3] 
{3-[4-(3-Aminopropyl)piperazin-1-yl]propyl}-(4-meth oxybenzyl)amine hydrochloride (11b)
Hydrochloride salt 11b was prepared from 10b in 98% yield as orange needles. Mp = 183-185 • C. 1 H NMR (DMSOd 6 ) δ: 2.02-2.17 (m, 4H, H-2, H-7); 2.89-3.01 (m, 4H, H-1, H-8); 3.25-3.80 (m, 12H, H-3, H-4, H-5, H-6) ; 3.77 (s, 3H, OCH 3 ); 4.06 (t, 2H, J = 5.3 Hz, H-9); 6.96-7.01 (m, 2H, H-3 , H-5 , Ar); 7.47-7.52 (m, 2H, H-2 , H-6 , Ar); 8.12 (br s, 3H, NH 2 , HCl); 9.35 (br s, 1H, NH). 13 {3- propyl}- (4-methy lbenzyl) 4H, 12H, 4.08 (t, 2H, J = 5.3 Hz, 2H, Ar); 2H, Ar); 8.15 (br s, 3H, NH 2 , HCl); 9.44 (br s, 1H, NH). 13 (C-8) ; 43.5 (C-4, C-5) ; 48.1 (C-9) ; 49.7 (C-3); 52.8 (C-6) ; 128.9 (C-2, C-6 , Ar); 129.2 Ar) ; 130.1 Ar); Ar) . ES + HRMS, m/z: 305.2701 found (calculated for C 18 H 33 N 4 [M+H] + requires 305.2700).
{3- propyl}- (4-chloro benzyl) 4H, 12H, 4.13 (t, 2H, J = 5.3 Hz, 2H, Ar); 2H, Ar); 8.24 (br s, 3H, NH 2 , HCl); 9.69 (br s, 1H, NH). 13 C NMR (DMSO-d 6 ) δ: 19.9 (C-7); 21.3 (C-2); 36.1 (C-1); 43.6 (C-8) ; 47.9 (C-4, C-5) ; 49.1 (C-9); 52.8 Ar) ; 130.9 (C-2 , C-6 , Ar); 132.2 Ar); Ar [1,3]dioxol-5-yl) 3H, Ar) . 13 C NMR (D 2 O) δ: 23.7 (C-2); 36.5 (C-1); 43.7 (C-3); 51.1 (C-4) ; 101.6 (OCH 2 O); 108.9 (C-2 , Ar); 109.9 Ar) ; 123.9 (C-6 , Ar); 124.2 (C-1 , Ar); 147.7 Ar); Ar 4.21 (s, 2H, 2H, J = 8.7 Hz, Ar); 2H, J = 8.7 Hz, Ar) . 13 C NMR (D 2 O) δ: 23.7 (C-2); 36.5 (C-1); 43.6 (C-3) ; 50.7 55.4 (OCH 3 ); Ar) ; 122.9 (C-1 , Ar); 131.5 Ar); Ar 
3-[(Benzo
3-(3-Methoxybenzylamino)propylamine hydrochloride (11g)
Hydrochloride salt 11g was prepared from 10g in 63% yield as brown yellow powder. 2H, 4H, 3.77 (s, 3H, OCH 3 ); 4.08 (t, 2H, J = 5.5 Hz, 1H, Ar); 1H, J = 7.6 Hz, Ar); 1H, Ar); 1H, Ar); 8.13 (br s, 3H, NH 2 , HCl); 9.43 (br s, 1H, NH). 13 3- (3, 4.19 (s, 2H, 6.67 (m, 3H, Ar) . 13 4, 13 C NMR (DMSO-d 6 ) δ: 23.7 (C-2); 36.2 (C-1); 43.5 (C-3); 50.3 (C-4) ; 56.1 (2 × OCH 3 ); 60.1 (OCH 3 ); 107.7 Ar); Ar); Ar); Ar 4.05 (s, 2H, 2H, J = 7.8 Hz, Ar); 2H, J = 8.0 Hz, Ar); 8.19 (br s, 3H, NH 2 , HCl); 9.50 (br s, 1H, NH). 13 C NMR (DMSO-d 6 ) δ: 20.9 (CH3); 23.6 (C-2); 36.2 (C-1); 43.5 (C-3) ; 49.8 (C-4) ; 128.9 (C-1 , Ar); 129.2 (C-2 , C-6 , Ar); 130.2 Ar); Ar 4.11 (t, 2H, J = 5.2 Hz, 2H, Ar); 2H, Ar); 8.22 (br s, 3H, NH 2 , HCl); 9.68 (br s, 1H, NH). 13 C NMR (DMSO-d 6 ) δ: 23.6 (C-2); 36.1 (C-1) ; 43.6 (C-3); 49.2 Ar); Ar) ; 132.2 (C-2 , C-6 , Ar); 133.7 Ar 2H, J = 8.4 Hz, Ar) . 13 To a suspension of {3- [4-(3-aminopropyl) piperazin-1-yl]-propyl}-arylamine hydrochloride 11(a-d) (0.19 mmol, 1 equiv.) in 10 mL of dry CH 2 Cl 2 under vigorous magnetic stirring (30 min to 1 h, 500 rpm) was added dropwise a solution of N , N -di-iso-propylethylamine DIPEA (49 mg, 0.38 mmol, 2 equiv.) in 6 mL of CH 2 Cl 2 over a period of 15-20 min at room temperature. After stirring at 25 • C during 1-2 h, ethyl 3-dimethylamino-2-(1H -benzimidazol-2-yl)acrylate 5 (49 mg, 0.19 mmol, 1 equiv.) was added in one portion in the reaction mixture, then the resulting suspension was refluxed for 24 h. After cooling down to room temperature, the yellow or yellow-orange reaction mixture was concentrated under reduced pressure in a rotary evaporator. To the crude residue was added appropriate volume of cooled deionized water (4 • C), and then mixing or triturating was pursued until complete precipitation. The insoluble compound 12 was collected by filtration on a Büchner funnel (porosity N • 4) and rinsed successively with deionized water (10-20 × 2 mL) and hexane (10-20 × 2 mL). For more information on work-up, see description for each product. The desired product 12 was dried under high vacuum (10 −2 Torr) during 1 h at 25 • C that gave a powder and was analyzed by 1 H, 3] 
Compound 12a was synthesized in 93% yield as gray powder according to the standard procedure (precipitation in 2 mL of deionized water and after filtration, washing with (10 × 2 mL) of deionized water and (3 × 2 mL) of hexane [1, 3] 
dioxol-5-ylmethyl)amino]propyl amino}-2-(1H-benzimidazol-2-yl)acrylate (12e)
Compound 12e was synthesized in 42% yield as yellow powder according to the standard procedure (precipitation in 3.5 mL of acetone under reflux for 1 h; mixing in 2 mL of Et 2 O during 5.5 h at 500 rpm, and after filtration on a Büchner funnel, the insoluble compound 12e was rinsed with 10 × 
Ethyl 3-(3-aminopropylamino)-2-(1H-benzimidazol-2-yl) acrylate hydrochloride (14)
Ethyl 2-(1H -benzimidazol-2-yl)-3-(3-tert-butyloxycar bonylaminopropylamino)acrylate 13 (0.1056 g, 0. 27 mmol, 1 equiv.) was solubilized in 2 mL of dry 1,4-dioxane at 25 • C under vigorous stirring (550 rpm) during 20 min. Then a solution of 6M HCl (2 mL) was added dropwise for 30 min in the homogeneous solution. The resulting mixture was stirred at 500 rpm during 4 h at 25 • C. and was concentrated in a rotary evaporator under reduced pressure for elimination of volatile compounds. To the crude reaction mixture was added 2 mL of anhydrous Et 2 O and after triturating, the insoluble salt 14 was collected by filtration on a Büchner funnel (porosity N • 4) and was dried under high vacuum (10 −2 Torr) at 25 • C for 4 h and gave the desired compound 14 in 72% yield as white powder. 1 H NMR (D 2 O) δ: 1.37 (t, 3H, J = 7.1 Hz, CH 2 CH 3 ); 2.04-2.14 (m, 2H, H-2 ); 3.08-3.13 (m, 2H, H-3 ); 3.62 (t, 2H, J = 6.9 Hz, H-1 ); 4.38-4.45 (q, 2H, J = 6.9 Hz, CH 2 CH 3 ); 7.38-7.41 (m, 2H, H-5, H-6, Ar); 7.52-7.55 (m, 2H, H-4, H-7, Ar); 8.00 (s, 1H, =CH). 13 (C-4, C-7) ; 124.9 (C-5, C-6) ; 130.0 (C-3a, C-7a); 149.3 (C-2); 157.0 (=CH); 166.79 (CO 2 Et). [1, 3] dioxol-5-ylmethylene)amino] propylamino} -2-(1H-benzimidazol-2-yl) acrylate (1 5) In a 10 mL glass tube (for microwave synthesis) were placed successively ethyl 3-(3-aminopropylamino)-2-(1H -benzimidazol-2-yl)acrylate hydrochloride 14 (14.2 mg, 0.044 mmol, 1 equiv.) , N , N -di-iso-propylethylamine DIPEA (8 μL, 6.1 mg, 0.0473 mmol, 1.075 equiv.), 3,4-(methylene dioxy)benzaldehyde 8a (6.6 mg, 0.044 mmol, 1 equiv.) and 1 mL of dry methanol. The glass tube was sealed with a snap cap and introduced in the microwave cavity of Monowave 300 Anton Paar reactor (P = 800 Watt). The reaction mixture was irradiated during 45 min at 90 • C under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and volatile compounds were eliminated in a rotary evaporator under reduced pressure. The desired aldimine 15 as yellowish viscous oil was dried under high vacuum (10 −2 Torr) at 25 • C for 20 min and further used without purification. Yield = 84%. 1 [1, 3] [1, 3] 
Ethyl 3-{3-[(benzo
Preparation of ethyl {3-[(benzo
dioxol-5-ylmethyl)ami no]propylamino}-2-(1H-benzimidazol-2-yl)acrylate (12e) by reduction of ethyl 3-{3-[(benzo
dioxol-5-ylmethylene) amino]propylamino}-2-(1H-benzimidazol-2-yl)acrylate (15)
Ethyl 3-{3-[(benzo [1, 3] dioxol-5-ylmethylene)amino]propylamino}-2-(1H -benzimidazol-2-yl)acrylate 15 (24.9 mg, 0.06 mmol, 1 equiv.) was solubilized in methanol (6-8 mL) under vigorous stirring (500 rpm) and cooled at 0 • C. To this solution was added by small portions commercial NaBH 4 (11.3 mg, 0.3 mmol, 5 equiv.) over a period of 20 minutes. The resulting suspension was stirred at 50 • C for 24 h. After cooling down to room temperature, volatile compounds were eliminated under reduced pressure with a rotary evaporator. To the crude residue was added 5 mL of deionized water and the resulting mixture was transferred into a separating funnel. Extraction was conducted with CH 2 Cl 2 (3 × 3 mL) and the combined organic phases were dried over magnesium sulfate MgSO 4 , filtered on filter paper, and solvent was eliminated in vacuo. The crude residue was dried under high vacuum (10 −2 Torr) at 25 • C for 2 h. The desired compound 12e was obtained as yellowish viscous oil and crystallized on standing. 12e was analyzed by 1 H, 13 C NMR. Yield = 51%. 
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